Cargando…
Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170279/ https://www.ncbi.nlm.nih.gov/pubmed/37181340 http://dx.doi.org/10.21037/atm-23-205 |
| _version_ | 1785039195372257280 |
|---|---|
| author | Crane, Harry Danta, Mark |
| author_facet | Crane, Harry Danta, Mark |
| author_sort | Crane, Harry |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10170279 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101702792023-05-11 Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data? Crane, Harry Danta, Mark Ann Transl Med Editorial Commentary AME Publishing Company 2023-02-27 2023-04-28 /pmc/articles/PMC10170279/ /pubmed/37181340 http://dx.doi.org/10.21037/atm-23-205 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Crane, Harry Danta, Mark Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data? |
| title | Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data? |
| title_full | Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data? |
| title_fullStr | Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data? |
| title_full_unstemmed | Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data? |
| title_short | Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data? |
| title_sort | aspirin, chronic hepatitis b (chb) and hepatocellular carcinoma (hcc)—will there ever be enough data? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170279/ https://www.ncbi.nlm.nih.gov/pubmed/37181340 http://dx.doi.org/10.21037/atm-23-205 |
| work_keys_str_mv | AT craneharry aspirinchronichepatitisbchbandhepatocellularcarcinomahccwillthereeverbeenoughdata AT dantamark aspirinchronichepatitisbchbandhepatocellularcarcinomahccwillthereeverbeenoughdata |